Industry News

Biotechnology Industry News

Boehringer Ingelheim has unveiled…

January 6th, 2026|FierceBiotech|

Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a deal worth potentially $120 million with genomics-focused Variant Bio.

In a strategic move that could…

January 6th, 2026|FierceBiotech|

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics.

A pair of phase 3 psoriasis…

January 6th, 2026|FierceBiotech|

A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu. With the

Instil Bio’s hopes for its…

January 6th, 2026|FierceBiotech|

Instil Bio’s hopes for its refreshed clinical pipeline appear to have ended in failure, with the U.S. biotech handing the rights to two drugs back to their original owner.

Less than two weeks after…

January 5th, 2026|FierceBiotech|

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the complete response letter, citing both efficacy and safety concerns, including a case of serious liver injury that led

Gilead Sciences has found a shiny…

January 5th, 2026|FierceBiotech|

Gilead Sciences has found a shiny new package for one of its cancer assets, inking an up to $300 million research pact for access to OncoNano Medicine’s tumor-targeting lipid particles.

MetaVia has shared an update on…

January 5th, 2026|FierceBiotech|

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who received its dual agonist of GLP-1 and glucagon in a phase 1 trial.

Sanofi has returned to U.S….

January 5th, 2026|FierceBiotech|

Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and immunology development pact.

The Singapore Eye Research…

January 5th, 2026|FierceBiotech|

The Singapore Eye Research Institute has pulled out of a collaboration with TME Pharma less than seven months after cementing their work on an eye disease program.

After five years, Nido Biosciences…

January 2nd, 2026|FierceBiotech|

After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study.

Ultragenyx Pharmaceutical has…

January 2nd, 2026|FierceBiotech|

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.